Drug Profile

Research programme: macrocyclic peptide drug conjugates - Novartis/PeptiDream

Latest Information Update: 06 May 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis; PeptiDream
Class Antineoplastics; Drug conjugates; Macrocyclic compounds; Peptides; Protein-drug conjugates; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
Mechanism of Action Diagnostic imaging enhancers; Ionising radiation emitters

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

30 Apr 2024 PeptiDream expands its peptide discovery collaboration with Novartis
31 Oct 2023 Preclinical trials in Solid tumours (Diagnosis) in Japan (unspecified route) (Peptidream Pipeline, April 2024)
31 Oct 2023 Preclinical trials in Solid tumours (Diagnosis) in Switzerland (unspecified route) (Peptidream Pipeline, April 2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com